Ongoing compliance is strengthened through continuous monitoring and periodic review of analytical data. Trend analysis enables early identification of deviations, allowing timely corrective and preventive actions.

Pharmaffiliates is proud to announce a remarkable achievement at the SME-Empowering India Awards 2025, where the organization was honored with three prestigious recognitions

Pharmaffiliates Private Limited recently hosted a vibrant and joyous Grand Diwali Celebration, bringing together employees, management, and their families in the spirit of unity and festivity.

Pharmaffiliates Pvt. Ltd. actively participated in the Swachhta Abhiyan organized in Industrial Area, Phase 2, Panchkula on 11-10-2025.

Pharmaffiliates Private Limited, based in Panchkula, India, has successfully developed and commercialized multiple high-value impurity standards..

Pharmaffiliates announces the first-time synthesis of multiple rare impurity standards, expanding its 100,000+ compound portfolio. With 24+ years of expertise, the company continues to support global pharma R&D with quality reference standards.

Pharmaffiliates, an end-to-end CRDMO services provider in India, will showcase spray dried dispersions, high-throughput screening, CHO DG44 biologics manufacturing, integrated process development, and monoclonal antibody analytics at CPHI Molkem.

Pharmaffiliates, an end-to-end CRDMO services provider in India, will showcase high-throughput screening, CHO DG44 biologics manufacturing, spray dried dispersions, and monoclonal antibody analytics at Analitica Brazil 2025.

Pharmaffiliates, an end-to-end CRDMO services provider in India, showcases expertise at Arab Lab with high-throughput screening, CHO DG44 biologics manufacturing, integrated process development, and monoclonal antibody analytics.

CRDMO Excellence India Pharmaffiliates CRDMO End-to-End CRDMO CDMO Partner India Trusted CRDMO India

CSR initiative lights up Golpura village with eco-friendly solar streetlights, improving safety, education, and community life.